Premium
Blood donor derived dendritic cells and cytotoxic T cells for specific fusion‐gene adoptive immunotherapy
Author(s) -
Gallagher R. C. J.,
Waterfall M.,
Samuel K.,
Turner M. L.
Publication year - 2007
Publication title -
vox sanguinis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.68
H-Index - 83
eISSN - 1423-0410
pISSN - 0042-9007
DOI - 10.1111/j.1423-0410.2006.00873.x
Subject(s) - cytotoxic t cell , adoptive immunotherapy , immunotherapy , immunology , fusion gene , medicine , adoptive cell transfer , cancer research , gene , biology , t cell , immune system , in vitro , genetics
Background and Objectives Therapeutic immunological reagents tailored to individual patients have been shown to be a viable treatment strategy for some forms of leukaemia. This work investigates the possibility of using blood donations as a source of leukaemia‐specific immune therapeutics. Materials and Methods The acute promyelocytic cell line NB4 carrying the PML‐RARα fusion was used as a target for cytotoxic T lymphocytes (CTL) stimulated to recognize the fusion. Stimulation of CTL was by production of dendritic cells pulsed with plasmid vectors containing polymerase chain reaction (PCR)‐generated sequences of PML‐RARα derived from NB4 cells. PCR primer design included a Kozak consensus sequence to allow correct translation of the nucleic acid into protein. Identification of specific cytotoxicity was by both Granzyme B ELISPOT and by 51 Cr‐release assays. Results Specific CTL activity targeting NB4 cells can be generated from donor‐derived peripheral blood mononuclear cells. However, individual donors appear to respond differently to the length of stimulatory sequence encoded in the vector. Use of an internal methionine in the PML gene, which also satisfies the Kozak rules, allows translation in vitro and, thus, might provide a suitable start site for stimulation using acute promyelocytic leukaemia‐specific sequence. Conclusion The work presented here suggests that blood donor derived dendritic cells can be used to stimulate leukaemia‐specific CTL from the same donation ex vivo . This would enable the generation of patient‐specific therapeutics from major histocompatibility (MHC)‐matched allogeneic donors. However, different MHC‐matched donors might vary in their response depending on the length of the antigenic sequence.